>
Powered by

CV Sciences, Inc. Announces Pre-IND Meeting Date with FDA

LAS VEGAS, NV --(Marketwired - May 02, 2017) - CV Sciences, Inc. (OTCQB: CVSI) (the "Company," "CV Sciences," "our" or "we"), is pleased to announce today that it will be meeting with the U.S. Food and Drug Administration (FDA) on June 15, 2017, to discuss its initial drug candidate (CVSI-007), a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco addiction.

According to the CDC, smokeless tobacco has bee

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox